Pharmaceutical

Biotech Industry Pharmaceutical

How to identify lead compounds in drug discovery

Identifying drug lead compounds, the starting point for drug development, is a crucial and multifaceted process. Here’s a breakdown of some key strategies employed in this scientific endeavor: 1. Target Identification and Validation: The journey begins...

Biotech GLP Industry Pharmaceutical

Keys for selecting preclinical drug candidate

Selecting a preclinical candidate is a critical step in drug development. It is a million dollars decision. It involves choosing the most promising drug molecule from a pool of candidates to move forward for further testing. Obviously, the...

GLP Pharmaceutical

Strategy for Planning IND-Enabling Safety Tests

IND-enabling safety tests are a crucial initial step in the drug development process. These tests help assess the safety profile of a new drug candidate before it can be administered to humans in clinical trials. Here’s...

Biotech Industry Pharmaceutical

What does BD do and how to become a BD in biotech

In the world of biotech, a Business Development (BD) professional plays a critical role in forging strategic partnerships, identifying and securing licensing deals, and driving the overall growth of the company. Here’s a breakdown of their...

GLP Pharmaceutical

Are there different GLP requirements or guidelines?

In the pharmaceutical industry, both FDA and OECD implement GLP (Good Laboratory Practice) guidelines aiming to ensure the quality and integrity of non-clinical safety studies. However, there are some key similarities and differences to consider: Similarities: Overall Goal: Both aim to...

Pharmaceutical Regulation

Comparison of FDA drug approval pathways in one table

The FDA (Food and Drug Administration) has several pathways for approving new drugs. Each track offers advantages and disadvantages depending on the urgency and data available for the medication. Here’s a breakdown of the four main...

Industry Pharmaceutical Regulation

Fluorine in the Spotlight – Review of the FDA’s 2023 New Drug

The FDA’s Center for Drug Evaluation and Research (CDER) approved 55 new molecular entities (NMEs) and new therapeutic biological products in 2023, including 33 small molecule drugs. Of these 33 small molecule drugs, 11 contain at...

GLP Pharmaceutical Regulation

How to conduct photosafety evaluation of Drugs

Abstract: With the increasing diversity of drug forms, the number of drugs involved in photosafety evaluation has also increased, and the frequency of photosafety being mentioned and discussed has also increased. In fact, many drugs can...

Biotech Industry Pharmaceutical

The consideration of working with pharmaceutical contract service organizations

The pharmaceutical industry has witnessed a paradigm shift, with contract service organizations (CSOs) emerging as powerful contributors across the spectrum of research, development, and manufacturing. These partnerships unlock access to specialized expertise, infrastructure, and economies of scale....

Chemical Pharmaceutical Sci&Tech

what is drug-like properties

Drug-like properties, also known as druglikeness, are a crucial concept in the pharmaceutical world. They describe the inherent characteristics of a molecule that influence its potential for successful drug development. In 2000, Christopher A. Lipinski proposed...